TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06524466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab
Description: SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT.
Study: NCT04893486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: QTORIN 3.9 % Sirolimus Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle comparator
Description: Vehicle comparator topical gel
Study: NCT05330221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAL2
Description: Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHARM-PAL2
Description: All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention.
Study: NCT05050201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepio
Description: Digital CBT application for insomnia
Study: NCT04914611

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05944523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spina Plan Block
Description: Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spina Plan Block
Description: Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
Study: NCT05460494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELOAD-C
Description: RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELOAD-C
Description: RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
Study: NCT05580627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livestream Modality (treatment)
Description: For this evaluation, the livestream modality is considered the treatment group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Modality (control)
Description: For this evaluation, the live modality is considered the control group.
Study: NCT06682663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Streaming Exercise
Description: Participants try to achieve 150 minutes of moderate-vigorous training per week. The exercise program includes live streaming exercise by trained health professionals, including pregnancy-specific exercises, with professional pregnancy trainers to provide guidance and support when needed.
Study: NCT06489470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strokectomy/Necrosectomy
Description: After obtaining CT-/MRT-perfusion, the infarcted area (e.g. infarct core) of malignant MCA-infarction is localized. By using the neuronavigation, surgical resection of necrotic tissue is performed in a non-eloquent area until the space occupying effect is released. At the end of the surgery, the bone flap is reinserted and fixated.
Study: NCT05152641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117, 4mg
Description: BGE-117, 4mg Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117, 4mg
Description: BGE-117, 4mg Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117, 4mg
Description: BGE-117, 4mg Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo to BGE-117 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117, 12mg
Description: BGE-117, 12mg Capsules
Study: NCT06128668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga will be applied
Study: NCT05253872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MelaCare intervention
Description: The primary principles applied will be:~* Meta-cognitive strategies and normalization of emotions~* Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~* An educational booklet~* Doctor consultation to ensure correct SSE skills and compliance to the protocol~* 3-5 sessions with a experienced and specially trained melanoma nurse~* Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae.
Study: NCT05474274

Intervention type: OTHER
Intervention: Machine learning algorithms
Description: Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
Study: NCT04711915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 mg/kg Dimethyltryptamine (DMT)
Description: 0.1 mg/kg DMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 mg/kg Dimethyltryptamine (DMT)
Description: 0.3 mg/kg DMT
Study: NCT06220357

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
Study: NCT06669624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Description: 10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Description: 10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist with 4-month delay, then ABC
Description: A 4-month waitlist period, after which they will also receive the home-based ABC program (same as Intervention group).
Study: NCT06678178

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (QR) Labels
Description: Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning High Climate Impact Labels
Description: Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
Study: NCT04169282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nPEP (non-invasive positive expiratory pressure) mask
Description: Positive end expiratory pressure (PEEP) mask
Study: NCT05079854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Instillation Solution
Description: Intracameral Moxifloxacin 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic
Description: Topical Moxifloxacin 0.5%
Study: NCT06328725

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EN001
Description: Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EN001
Description: Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.
Study: NCT06375018

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Technique
Description: In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm Stretching
Description: The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
Study: NCT06275087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
Study: NCT06678178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traffic Light Labels
Description: Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Climate Grade Labels
Description: Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numeric Carbon Footprint Labels
Description: Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
Study: NCT06246786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
Study: NCT04967417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, Carboplatin, Pembrolizumab
Description: * Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin, Pembrolizumab
Description: * Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg
Study: NCT06700343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (US)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (EU)
Description: IV infusion
Study: NCT04675983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT06700343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 692
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 692
Description: IV infusion
Study: NCT04675983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally
Study: NCT04658875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina maxima supplementation
Description: Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina maxima supplementation
Description: Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
Study: NCT06731881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal PDT
Description: Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Photosensitizer formulation only
Description: Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.
Study: NCT04658875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wash-out
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash-out
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash-out
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash-out
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplementation
Description: Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo supplementation
Description: Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic physical exercise program
Description: Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
Study: NCT06731881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal culture
Description: Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal culture
Description: Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Flexible nasendoscopy
Description: Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).
Study: NCT04658875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic physical exercise program
Description: Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.